for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shanghai Fosun Pharmaceutical (Group)

2196.HK

Latest Trade

23.30HKD

Change

0.45(+1.97%)

Volume

8,638,758

Today's Range

22.90

 - 

23.65

52 Week Range

19.76

 - 

31.50

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
22.85
Open
23.10
Volume
8,638,758
3M AVG Volume
67.14
Today's High
23.65
Today's Low
22.90
52 Week High
31.50
52 Week Low
19.76
Shares Out (MIL)
2,562.90
Market Cap (MIL)
73,668.65
Forward P/E
15.81
Dividend (Yield %)
1.58

Latest Developments

更多

Shanghai Fosun Pharmaceutical Group Says Fosun High Tech Bought 1.1 Mln H Shares

Fosun International Says Final Offer Price Of Shanghai Henlius H Shares Is HK$49.60/ Share

Shanghai Fosun Pharmaceutical's H1 Net Profit Down 2.8% Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shanghai Fosun Pharmaceutical (Group)

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company's products are mainly applied in the treatment of metabolism and digestive tract system, cardiovascular system, central nervous system, blood system, anti-tumor and anti-infection diseases. The Company is also engaged in medical equipment and medical diagnosis business, as well as the provision of medical services. It distributes its products primarily in domestic and overseas markets.

Industry

Major Drugs

Contact Info

Building A, No. 1289 Yishan Road

+86.21.33987870

http://www.fosunpharma.com

Executive Leadership

Qiyu Chen

Chairman of the Board, Executive Director

Fang Yao

Co-Chairman of the Board, Executive Director

Yifang Wu

President, Chief Executive Officer, Executive Director

Xiaohui Guan

Chief Financial Officer, Senior Vice President, Chief Accounting Officer

Yuqing Chen

Senior Vice President

Key Stats

2.22 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

14.5K

2017

18.4K

2018

24.7K

2019(E)

29.5K
EPS (CNY)

2016

1.200

2017

1.270

2018

1.070

2019(E)

1.292
Price To Earnings (TTM)
19.85
Price To Sales (TTM)
2.47
Price To Book (MRQ)
1.85
Price To Cash Flow (TTM)
14.58
Total Debt To Equity (MRQ)
84.60
LT Debt To Equity (MRQ)
52.33
Return on Investment (TTM)
7.09
Return on Equity (TTM)
4.44

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up